1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Nippon Chemiphar Co., Ltd.

Nippon Chemiphar Co., Ltd.

TTSE:4539
1,542.00
JPY
+7.00
(+0.46%)
6.45BMarket Cap
Oct 30Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
7,806.96
8,772.4
9,059.57
9,207.83
9,598.86
9,507.22
8,833.35
8,773.62
9,013.11
8,743.53
8,520.2
9,026.85
9,156.73
- -
Basic EPS, GAAP
461.91
474.35
499.01
529.92
315.15
245.04
121.28
137.69
194.09
93.92
-49.88
81.48
54.79
- -
Free Cash Flow per Basic Share
463.14
608.99
623.45
706.13
866.13
610.79
263.13
-23.64
297.79
-534.71
-648.41
-588.39
-91.04
- -
Dividend per Share
100.85
100.67
102.55
101.65
104.6
101.24
101.25
50.63
50.46
50.7
50.43
50.44
50.36
- -
Book Value per Share
3,372.22
3,901.5
4,101.59
4,550.97
4,862.9
4,967.69
4,837.23
5,010.7
5,124.58
5,134.98
5,115.78
5,312.42
5,382.16
- -
Tangible Book Value per Share
3,310.27
3,877.53
4,085.74
4,533.93
4,793.1
4,863.39
4,747.1
4,665.21
4,879.72
4,977.33
5,037.91
5,175.5
5,244.49
- -
Basic Weighted Avg Shares
4
4
4
4
4
4
4
4
4
4
4
4
4
4
Sales/Revenue/Turnover
31,893
35,119
35,602
35,690
35,331
34,182
31,757
31,541
32,506
31,559
30,748
32,570
33,090
- -
Operating Margin (%)
10.43
9.35
8.83
7.95
5.23
4.28
1.15
1.79
2.54
-0.76
-1.61
1.86
0.54
- -
Depreciation Expense
1,035
1,351
1,199
1,112
1,192
1,345
1,272
1,393
1,586
1,500
1,459
1,377
1,559
- -
Net Income, GAAP
1,887
1,899
1,961
2,054
1,160
881
436
495
700
339
-180
294
198
- -
Effective Tax Rate (%)
38.2
38.57
33.45
27.87
34.67
39.34
40.44
30.58
28.18
29.38
- -
- -
10.41
- -
Profit Margin (%)
5.92
5.41
5.51
5.76
3.28
2.58
1.37
1.57
2.15
1.07
-0.59
0.9
0.6
- -
Working Capital
8,792
10,905
11,723
14,070
12,857
14,843
15,575
16,344
16,745
18,670
18,050
17,805
17,245
- -
LT Debt
8,924
9,672
9,154
12,172
11,967
12,594
11,935
12,479
11,534
12,111
13,526
14,427
13,233
- -
Total Equity
13,501
15,626
16,041
17,355
17,485
17,860
17,390
18,013
18,501
18,533
18,460
19,167
19,509
- -
Return on Invested Capital (%)
7.9
7.14
7.01
6.51
3.66
2.66
0.65
1.18
1.76
-0.5
- -
- -
0.44
- -
Return on Capital (%)
7.94
7.31
7.12
6.96
3.84
2.91
1.55
1.76
2.35
1.27
- -
- -
1.09
- -
Return on Common Equity (%)
14.57
13.04
12.39
12.3
6.66
4.99
2.47
2.8
3.83
1.83
-0.97
1.56
1.02
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
3,778
3,351
- -
LT Borrowings
13,440
12,297
- -
LT Finance Leases
1,034
936
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
5,819
6,452
5,671

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
32,554
29,941
- -
Cash, Cash Equivalents & STI
9,001
5,342
- -
Accounts Receivable, Net
7,097
8,179
- -
Inventories
12,421
12,892
- -
Total Current Liabilities
13,816
12,696
- -
Payables & Accruals
- -
- -
- -
ST Debt
3,778
3,351
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.01%
1.62%
1.78%
Free Cash Flow
-188.46%
-343.15%
-84.5%
Net Income, GAAP
-55.9%
-91.85%
-32.65%
Sales/Revenue/Turnover
-0.67%
1.02%
1.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
32,570
2026
- -
- -
- -
- -
33,090
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
81.48
2026
- -
- -
- -
- -
54.79
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
50.44
2026
- -
- -
- -
- -
50.36
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kazushiro Yamaguchi
Full Time Employees
878
Sector
Health technology
Industry
Pharmaceuticals: major
Address
2-2-3, Iwamoto-cho Tokyo TY Japan 101-0032
IPO Date
Oct 1, 1971
Website
chemiphar.co.jp
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Nippon Chemiphar Co., Ltd. (TSE: 4539) manufactures and markets generic and branded pharmaceuticals in Japan. The company produces a diverse portfolio of prescription drugs, including generic medications in categories such as antihypertensives, antidiabetics, cholesterol-lowering agents, antiulcerants, and antibiotics; branded products like the osteoporosis treatment Alendronate and the gout medication Febuxostat; over-the-counter (OTC) drugs; and contract manufacturing services for other pharmaceutical firms. Nippon Chemiphar operates primarily in the Japanese market, serving hospitals, clinics, pharmacies, and wholesalers through its domestic sales network. Founded in 1924 and headquartered in Hikone, Shiga Prefecture, Japan, the company focuses on cost-effective generic drug development and production to support Japan's healthcare system amid rising medical costs. In recent developments, Nippon Chemiphar expanded its generic portfolio with new launches including bioequivalent versions of key drugs in 2024; formed a strategic distribution alliance with a major wholesaler to enhance market penetration; and completed a minor acquisition of a small compounding facility in 2025 to bolster production capacity, reflecting its ongoing commitment to operational efficiency and growth in the competitive generics sector.